Malaysia
Search
Sign In
Change Password
Points
Sign Out
Top Medical News
Concentrations of biologics in breast milk samples from women being treated for inflammatory bowel disease appear to be low, a study has found. Furthermore, breastfed infants of mothers on biologics, immunomodulators or combination therapies have comparable risk of infection and rate of milestone achievement as nonbreastfed infants or those unexposed to such drugs.
Dr Jarrod Lee, a gastroenterologist and advanced endoscopist at gutCARE, Singapore, shares his insights with Pearl Toh on diagnosing and managing diarrhoea in the primary care setting.
Continued follow-up study of individuals at high risk of pancreatic ductal adenocarcinoma (PDAC) leads to successful detection of resectable tumours and high-grade precursor neoplasms, as shown in a recent study.
High-dose esomeprazole in combination with aspirin can moderately reduce the risk of developing high-grade dysplasia or oesophageal cancer or delay death from any cause in patients with Barrett’s oesophagus (BE).
Bezafibrate + ursodeoxycholic acid suitable as second-line treatment for primary biliary cholangitis
The addition of bezafibrate to ursodeoxycholic acid improves biochemical responses over ursodeoxycholic acid alone in patients with primary biliary cholangitis, according to results of the BEZURSO* trial.
There is an increasing number of studies that shed light on the importance of our gut microbiota. Probiotics are live microorganisms that confer health benefits on the host when administered in adequate amounts. With new data emerging about their proposed benefits in maintaining intestinal health, probiotics continue to gain popularity amongst consumers.
The likelihood of restarting treatment with direct oral anticoagulants (DOACs) following gastrointestinal bleeding (GIB) appears to be low among older patients who require blood and intensive care, a study has shown. Furthermore, a history of venous thromboembolism and thienopyridine use are risk factors for subsequent thromboembolism and GIB, respectively.
Special Reports
There is an increasing number of studies that shed light on the importance of our gut microbiota. Probiotics are live microorganisms that confer health benefits on the host when administered in adequate amounts. With new data emerging about their proposed benefits in maintaining intestinal health, probiotics continue to gain popularity amongst consumers.
Advancements in genomics has paved the way for better classifications of colorectal cancers (CRC) and the use of precision therapy.
In this issue of MIMS Gastroenterology Supplement, we bring you clinical updates related to hepatitis B, and also a symposium highlight in conjunction with the launch of tenofovir disoproxil fumarate (Ricovir®; Mylan Laboratories) in Malaysia.
Last August, the article 'Role of General Practitioners in Early Detection of Inflammatory Bowel Disease' highlighted proper screening and early specialist referral by the general practitioner (GP) as vital components in reducing the burden of inflammatory bowel disease (IBD). This year, the focus is on the role of GPs in co-managing a patient with IBD at the follow-up phase.
Nonalcoholic fatty liver disease (NAFLD), including simple steatosis and nonalcoholic steatohepatitis (NASH), is widely considered as the liver manifestation of the metabolic syndrome. It is a major cause of liver disease worldwide and its prevalence is expected to rise in tandem with the rising prevalence of obesity and diabetes mellitus. Recently, MIMS Doctor spoke to Associate Professor Dr Wah Kheong Chan, a Consultant Physician and Gastroenterologist at the University of Malaya Medical Centre and University of Malaya Specialist Centre, to provide an update on NAFLD, with a particular emphasis on the use of silymarin for the treatment of NASH. Here are the highlights from the interview.
Constipation is a common disorder which adversely affects the wellbeing and quality of life of patients.1 Recently, MIMS Doctor spoke to Associate Prof Dr Raja Affendi Raja Ali on the landscape of constipation in Malaysia, emphasizing on effective and early management of the condition.
DUKORAL – Inactivated Vibrio cholerae O1 serogroup & recombinant cholera toxin B subunit (WC/rCTB) vaccine (oral) – AJ Biologics
Conference Reports
A weekly dose escalation of regorafenib was superior to starting with the standard dose of 160 mg/day for patients with refractory metastatic colorectal cancer (mCRC), according to the ReDOS* trial presented at the ASCO GI Cancers Symposium 2018.
Patients with inflammatory bowel disease (IBD) who had primary nonresponse ─ or inadequate response to the initial loading doses ─ to an anti-tumour necrosis factor (TNF) agent were less likely to respond to second-line biologics compared with those who had secondary loss of response (LOR) or intolerance to the primary therapy, according to a systematic review and meta-analysis presented at the Crohn's & Colitis Congress (CCC) 2018 held recently in Las Vegas, Nevada, US.
Studies demonstrate conflicting findings on impact of obesity on treatment response, outcomes in IBD
Obesity does not appear to have a significant influence on treatment response and clinical outcomes in patients with inflammatory bowel disease (IBD), according to two studies presented at the 2018 Crohn’s & Colitis Congress (CCC).
Use of the gut-selective anti-integrin monoclonal antibody vedolizumab was associated with favourable treatment outcomes in patients with inflammatory bowel diseases (IBD) such as ulcerative colitis and Crohn’s disease, according to studies presented at the 2018 Crohn’s & Colitis Congress (CCC).
Pembrolizumab demonstrated promising results in several outcomes among patients with advanced hepatocellular carcinoma (HCC) whose disease progressed on or who were unable to tolerate treatment with sorafenib, findings from the KEYNOTE-224* trial show.
Rifaximin, an antibiotic that has been approved for treating IBS-D*, may also benefit patients with Crohn's disease (CD), suggests a study presented at the Crohn's & Colitis Congress (CCC) 2018.
Using the JAK* inhibitor tofacitinib as induction therapy for Crohn’s disease (CD) can promote disease remission in certain patients selected based on baseline endoscopic evidence of inflammation, according to a post hoc analysis presented at the recent Crohn's & Colitis Congress (CCC) 2018, Las Vegas, Nevada, US.
.jpg)
